Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 542395, 10 pages
http://dx.doi.org/10.1155/2014/542395
Research Article

Cytogenetic as an Important Tool for Diagnosis and Prognosis for Patients with Hypocellular Primary Myelodysplastic Syndrome

1Bone Marrow Transplantation Center, National Cancer Institute (INCA), 20230-130 Rio de Janeiro, RJ, Brazil
2Mathematical and Statistical Institute of Federal Fluminense University (UFF), 24020-140 Niterói, RJ, Brazil
3Arthur Siqueira Cavalcanti Hematology Institute (HEMORIO), 20211-030 Rio de Janeiro, RJ, Brazil
4Hematology Service, National Cancer Institute (INCA), 20230-130 Rio de Janeiro, RJ, Brazil
5Pediatric and Puericulture Martagão Gesteira Institute, Federal University of Rio de Janeiro, 21941-590 RJ, Brazil

Received 28 February 2014; Accepted 7 July 2014; Published 11 August 2014

Academic Editor: Emin Karaca

Copyright © 2014 Daiane Corrêa de Souza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. D. Nimer, “Myelodysplastic syndromes,” Blood, vol. 111, no. 10, pp. 4841–4851, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. C. M. Niemeyer and I. Baumann, “Myelodysplastic syndrome in children and adolescents,” Seminars in Hematology, vol. 45, no. 1, pp. 60–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. T. Elghetany, “Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series,” Archives of Pathology & Laboratory Medicine, vol. 131, no. 7, pp. 1110–1116, 2007. View at Google Scholar · View at Scopus
  4. N. Tuzuner, C. Cox, J. M. Rowe, D. Watrous, and J. M. Bennett, “Hypocellular myelodysplastic syndromes (MDS): new proposals,” British Journal of Haematology, vol. 91, no. 3, pp. 612–617, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Tomonaga and K. Nagai, “Hypocellular myelodysplastic syndromes and hypocellular acute myeloid leukemia: relationship to aplastic anemia,” in The Myelodysplastic Syndromes: Pathobiology and Clinical Management, pp. 121–138, Marcel Dekker, New York, NY, USA, 2002. View at Google Scholar
  6. G. Yue, S. Hao, O. Fadare et al., “Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome,” Leukemia Research, vol. 32, no. 4, pp. 553–558, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Haase, “Cytogenetic features in myelodysplastic syndromes,” Annals of Hematology, vol. 87, no. 7, pp. 515–526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Kawankar, F. Jijina, K. Ghosh, and B. R. Vundinti, “Cytogenetic and comparative genomic hybridization study of Indian myelodysplastic syndromes,” Cancer Epidemiology, vol. 35, no. 4, pp. e1–e5, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. U. Bacher, W. Kern, T. Alpermann, S. Schnittger, C. Haferlach, and T. Haferlach, “Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course,” Leukemia Research, vol. 36, no. 7, pp. 826–831, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. T. S. Fernandez, M. H. Ornellas, L. Otero, D. Tabak, and E. Abdelhay, “Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia,” Leukemia Research, vol. 24, no. 10, pp. 839–848, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Marisavljević, V. Čemerikić, Z. Rolović, D. Bošković, and M. Čolović, “Hypocellular myelodysplastic syndromes: clinical and biological significance,” Medical Oncology, vol. 22, no. 2, pp. 169–175, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. T. C. Huang, B. S. Ko, J. L. Tang et al., “Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies,” Leukemia, vol. 22, no. 3, pp. 544–550, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Qu, Z. Xu, Y. Zhang et al., “Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study,” Leukemia & Lymphoma, vol. 53, no. 5, pp. 940–946, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Wang, X. Q. Wang, X. P. Xu, and G. Lin, “Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome,” Cancer Genetics and Cytogenetics, vol. 196, no. 2, pp. 159–166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Greenberg, C. Cox, and M. M. Le Beau, “International scoring system for evaluating prognosis in myelodysplastic syndromes,” Blood, vol. 89, no. 6, pp. 2079–2088, 1997. View at Google Scholar · View at Scopus
  16. J. M. Bennett, D. Catovsky, and M. T. Daniel, “Proposals for the classification of the myelodysplastic syndromes,” British Journal of Haematology, vol. 51, no. 2, pp. 189–199, 1982. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Hasle, C. M. Niemeyer, J. M. Chessells et al., “A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases,” Leukemia, vol. 17, no. 2, pp. 277–282, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. L. G. Shaffer, J. McGowan-Jordan, and M. Schmid, ISCN: An International System for Human Cytogenetic Nomenclature, S. Karger, Basel, Switzerland, 2013.
  19. B. L. Ebert, J. Pretz, J. Bosco et al., “Identification of RPS14 as a 5q- syndrome gene by RNA interference screen,” Nature, vol. 451, no. 7176, pp. 335–339, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Kaneko, S. Misawa, S. Horiike, H. Nakai, and K. Kashima, “TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities,” Blood, vol. 85, no. 8, pp. 2189–2193, 1995. View at Google Scholar · View at Scopus
  21. C. G. T. Silveira, F. M. Oliveira, E. T. Valera et al., “New recurrent deletions in the PPARγ and TP53 genes are associated with childhood myelodysplastic syndrome,” Leukemia Research, vol. 33, no. 1, pp. 19–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Sebaa, L. Ades, F. Baran-Marzack et al., “Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion,” Genes Chromosomes and Cancer, vol. 51, no. 12, pp. 1086–1092, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. R. A. Alharbi, R. Pettengell, H. S. Pandha, and R. Morgan, “The role of HOX genes in normal hematopoiesis and acute leukemia,” Leukemia, vol. 27, no. 5, pp. 1000–1008, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. E. F. Rodrigues, C. B. Santos-Rebouças, M. M. Gonçalves Pimentel et al., “Epigenetic alterations of p15INK4B and p16INK4A genes in pediatric primary myelodysplastic syndrome,” Leukemia & Lymphoma, vol. 51, no. 10, pp. 1887–1894, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Alfaro, Á. Pérez-Granero, M. A. Durán, J. Besalduch, J. Rosell, and M. Bernués, “dup(1)(q21q32) as a sole cytogenetic event is associated to a leukemic transformation in Myelodysplastic Syndromes,” Leukemia Research, vol. 32, no. 1, pp. 159–161, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Mani, D. E. Carrasco, Z. Yunyu et al., “BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells,” Cancer Research, vol. 69, no. 19, pp. 7577–7586, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Eguchi, M. Eguchi-Ishimae, and M. Greaves, “Molecular pathogenesis of MLL-associated leukemias,” International Journal of Hematology, vol. 82, no. 1, pp. 9–20, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. T. D. S. Fernandez, M. L. M. Silva, J. De Souza, M. T. M. De Paula, and E. Abdelhay, “C-MYC amplification in a case of progression from MDS to AML (M2),” Cancer Genetics and Cytogenetics, vol. 86, no. 2, pp. 183–184, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. P. L. Greenberg, H. Tuechler, J. Schanz et al., “Revised international prognostic scoring system for myelodysplastic syndromes,” Blood, vol. 120, no. 12, pp. 2454–2465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. E. F. Rodrigues, D. C. de Souza, A. Camargo et al., “Cytogenetic biclonality in a child with hypocellular primary myelodysplastic syndrome,” Cancer Genetics and Cytogenetics, vol. 178, no. 1, pp. 70–72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. T. de Souza Fernandez, M. H. Ornellas, R. de Cássia Tavares et al., “Hyperdiploid karyotype in a child with hypocellular primary myelodysplastic syndrome,” European Journal of Haematology, vol. 71, no. 5, pp. 399–401, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Glaubach, L. J. Robinson, and S. J. Corey, “Pediatric myelodysplastic syndromes: they do exist!,” Journal of Pediatric Hematology Oncology, vol. 36, no. 1, pp. 1–7, 2014. View at Google Scholar
  33. W. Tong, A. Quintás-Cardama, T. Kadia et al., “Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system,” Cancer, vol. 118, no. 18, pp. 4462–4470, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. U. Bacher, C. Haferlach, N. Kröger et al., “Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes,” Biology of Blood and Marrow Transplantation, vol. 16, no. 1, pp. 1–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. J. E. Anderson, “Allogeneic bone marrow transplantation in myelodysplastic syndrome,” in The Myelodysplastic Syndromes: Pathobiology and Clinical management, pp. 435–464, Marcel Dekker, New York, NY, USA, 2002. View at Google Scholar
  36. E. P. Alessandrino, M. G. D. Porta, L. Malcovati et al., “Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome,” American Journal of Hematology, vol. 88, no. 7, pp. 581–588, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Makishima, M. Rataul, L. P. Gondek et al., “FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q),” Leukemia Research, vol. 34, no. 4, pp. 447–453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. D. C. de Souza, A. F. de Figueiredo, H. Mkrtchyan et al., “A yet unreported der(11)t(6;11)(p21;q21) included in a complex karyotype of a refractory anemia with ring sideroblasts and poor prognosis,” Blood Cells, Molecules and Diseases, vol. 53, no. 1-2, pp. 91–93, 2014. View at Publisher · View at Google Scholar
  39. Z. K. Otrock, R. V. Tiu, J. P. Maciejewski, and M. A. Sekeres, “The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?” Expert Review of Hematology, vol. 6, no. 1, pp. 59–68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Gisselsson, “Cytogenetic methods,” in Cancer Cytogenetics, S. Heim and F. Mitelman, Eds., pp. 9–16, Wiley-Blackwell, 3rd edition, 2009. View at Google Scholar